Nature Communications (Oct 2020)
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
- Yifei Zhang,
- Yanyun Gu,
- Huahui Ren,
- Shujie Wang,
- Huanzi Zhong,
- Xinjie Zhao,
- Jing Ma,
- Xuejiang Gu,
- Yaoming Xue,
- Shan Huang,
- Jialin Yang,
- Li Chen,
- Gang Chen,
- Shen Qu,
- Jun Liang,
- Li Qin,
- Qin Huang,
- Yongde Peng,
- Qi Li,
- Xiaolin Wang,
- Ping Kong,
- Guixue Hou,
- Mengyu Gao,
- Zhun Shi,
- Xuelin Li,
- Yixuan Qiu,
- Yuanqiang Zou,
- Huanming Yang,
- Jian Wang,
- Guowang Xu,
- Shenghan Lai,
- Junhua Li,
- Guang Ning,
- Weiqing Wang
Affiliations
- Yifei Zhang
- National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Yanyun Gu
- National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Huahui Ren
- BGI-Shenzhen
- Shujie Wang
- National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Huanzi Zhong
- BGI-Shenzhen
- Xinjie Zhao
- Dalian Institute of Chemical Physics, Chinese Academy of Science
- Jing Ma
- Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine
- Xuejiang Gu
- The First Affiliated hospital of Wenzhou Medical University
- Yaoming Xue
- Nanfang Hospital, Southern Medical University
- Shan Huang
- Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine
- Jialin Yang
- Central Hospital of Minhang District
- Li Chen
- Qilu Hospital of Shandong University
- Gang Chen
- Fujian Provincial Hospital
- Shen Qu
- Shanghai Tenth People’s Hospital of Tong Ji University
- Jun Liang
- Xuzhou Central Hospital
- Li Qin
- Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine
- Qin Huang
- Chang Hai Hospital, Second Military Medical University
- Yongde Peng
- Shanghai First People’s Hospital, Shanghai Jiao Tong University School of Medicine
- Qi Li
- Dalian Institute of Chemical Physics, Chinese Academy of Science
- Xiaolin Wang
- Dalian Institute of Chemical Physics, Chinese Academy of Science
- Ping Kong
- BGI-Shenzhen
- Guixue Hou
- BGI-Shenzhen
- Mengyu Gao
- BGI-Shenzhen
- Zhun Shi
- BGI-Shenzhen
- Xuelin Li
- National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Yixuan Qiu
- National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Yuanqiang Zou
- BGI-Shenzhen
- Huanming Yang
- BGI-Shenzhen
- Jian Wang
- BGI-Shenzhen
- Guowang Xu
- Dalian Institute of Chemical Physics, Chinese Academy of Science
- Shenghan Lai
- Johns Hopkins University School of Medicine
- Junhua Li
- BGI-Shenzhen
- Guang Ning
- National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Weiqing Wang
- National Clinical Research Centre for Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-18414-8
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
The gut microbiome affects systemic metabolism and is a therapeutic target for type 2 diabetes. Here the authors demonstrate in a randomized controlled trial that effects of berberine, a plant alkaloid known to lower blood glucose, may be explained by the inhibition of Ruminococcus bromii mediated biotransformation of the bile acid deoxycholic acid.
